Search - tctmd.com

Displaying 41 - 60 of 163

Sort: Relevancy | Date

Presentation The Structural Heart Disease Summit 2018

Keynote Lecture #3: A Deep Dive Into TAVR Cost-effectiveness Studies - Take-home Messages

Presenter: David J. Cohen

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: Howard C. Herrmann, Allan Schwartz, Philippe Genereux

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: Howard C. Herrmann, Allan Schwartz, Nicolas M. Van Mieghem

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Keynote Lecture #2: Useful and Evolving Biomarkers in Aortic Stenosis and TAVR - Current Status and Future Directions

Presenter: Brian R Lindman

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Conductor (Illustrative Cases)

Presenter: John Forrest

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Program Update: The Evolut R/PRO TAVR System: Design Characteristics, Clinical Data, and Future Vision

Presenter: Axel Linke, Vinod H. Thourani, Jeffrey J. Popma

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Keynote Lecture #1: New AS Classification Scheme Based on Cardiac Damage - Changes After AVR

Presenter: Philippe Genereux

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Double Device Harmony for Challenging Anatomy

Presenter: Horst Sievert, Robert J. Sommer, David Meerkin

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

A Clinical Algorithm for Diagnosing and Managing Patients With Low-Flow, Low-Gradient Aortic Stenosis

Presenter: Howard C. Herrmann, Allan Schwartz

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Central Aortic Insufficiency Due to Transcatheter Heart Valve Defect After Transapical Transcatheter Aortic Valve Replacement

Presenter: A. Pieter Kappetein, Dee Dee Wang, Chad Morreale, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Combined TAVR With Sapien 3 Valve and Paravalvular Leak Closure for Severe Paravalvular Leak

Presenter: A. Pieter Kappetein, Dee Dee Wang, Cenap Undemir, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Transcatheter Aortic Valve Replacement for Severe Aortic Insufficiency in a Patient With Prior Type A Aortic Dissection Repair and Residual Type B Dissection Extending to the Infrarenal Aorta

Presenter: A. Pieter Kappetein, Dee Dee Wang, Hasan Ahmad, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Counterpoint: A "Selective" Minimalist Strategy Makes More Sense, and "Extreme" Minimalism Is Dangerous!

Presenter: Eberhard Grube, Howard C. Herrmann, Susheel K. Kodali

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve With Left Ventricular Outflow Tract Aneurysm

Presenter: A. Pieter Kappetein, Dee Dee Wang, Arijit Chanda, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Point: A Minimalist Strategy Should Be Used in ALL TAVR Patients!

Presenter: Eberhard Grube, Howard C. Herrmann, Vinod H. Thourani

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

ViV in a Patient With a "Ghost" Valve and Extremely Low Left Main Trunk Takeoff

Presenter: A. Pieter Kappetein, Dee Dee Wang, Costantino Costantini, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Contemporaneous Transcatheter Heart Valve Replacement in Native Aortic and Mitral Valve Stenosis

Presenter: Isaac George, Christopher U. Meduri, Marcus R. Burns

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presenter: Susheel K. Kodali, Michael J. Reardon, Patrick M. McCarthy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Presenter: Susheel K. Kodali, Michael J. Reardon, Mathew Williams

June 21, 2018

News Conference News The Structural Heart Disease Summit 2018

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Shelley Wood

June 21, 2018

Advertisement

Keynote Lecture #3: A Deep Dive Into TAVR Cost-effectiveness Studies - Take-home Messages

Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Keynote Lecture #2: Useful and Evolving Biomarkers in Aortic Stenosis and TAVR - Current Status and Future Directions

Conductor (Illustrative Cases)

Program Update: The Evolut R/PRO TAVR System: Design Characteristics, Clinical Data, and Future Vision

Keynote Lecture #1: New AS Classification Scheme Based on Cardiac Damage - Changes After AVR

Double Device Harmony for Challenging Anatomy

A Clinical Algorithm for Diagnosing and Managing Patients With Low-Flow, Low-Gradient Aortic Stenosis

Central Aortic Insufficiency Due to Transcatheter Heart Valve Defect After Transapical Transcatheter Aortic Valve Replacement

Combined TAVR With Sapien 3 Valve and Paravalvular Leak Closure for Severe Paravalvular Leak

Transcatheter Aortic Valve Replacement for Severe Aortic Insufficiency in a Patient With Prior Type A Aortic Dissection Repair and Residual Type B Dissection Extending to the Infrarenal Aorta

Counterpoint: A "Selective" Minimalist Strategy Makes More Sense, and "Extreme" Minimalism Is Dangerous!

Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve With Left Ventricular Outflow Tract Aneurysm

Point: A Minimalist Strategy Should Be Used in ALL TAVR Patients!

ViV in a Patient With a "Ghost" Valve and Extremely Low Left Main Trunk Takeoff

Contemporaneous Transcatheter Heart Valve Replacement in Native Aortic and Mitral Valve Stenosis

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content